Cargando…

Use of intravenous N-acetylcysteine in acute severe hepatitis due to severe dengue infection: a case series

BACKGROUND: Dengue fever is a common mosquito borne viral infection. Severe dengue fever associated severe hepatitis carries high mortality. Based on the beneficial effect of N-acetylcysteine (NAC) in paracetamol poisoning and non-acetaminophen induced liver failure, it is used in dengue fever assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Dissanayake, D. M. D. I. B., Gunaratne, W. M. S. N., Kumarihamy, K. W. M. P. P., Kularatne, S. A. M., Kumarasiri, P. V. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454086/
https://www.ncbi.nlm.nih.gov/pubmed/34544380
http://dx.doi.org/10.1186/s12879-021-06681-9
_version_ 1784570416279322624
author Dissanayake, D. M. D. I. B.
Gunaratne, W. M. S. N.
Kumarihamy, K. W. M. P. P.
Kularatne, S. A. M.
Kumarasiri, P. V. R.
author_facet Dissanayake, D. M. D. I. B.
Gunaratne, W. M. S. N.
Kumarihamy, K. W. M. P. P.
Kularatne, S. A. M.
Kumarasiri, P. V. R.
author_sort Dissanayake, D. M. D. I. B.
collection PubMed
description BACKGROUND: Dengue fever is a common mosquito borne viral infection. Severe dengue fever associated severe hepatitis carries high mortality. Based on the beneficial effect of N-acetylcysteine (NAC) in paracetamol poisoning and non-acetaminophen induced liver failure, it is used in dengue fever associated hepatitis in clinical practice. We aim to study the reversal of liver enzymes with NAC in the setting of severe hepatitis due to severe dengue infection. METHODS: A retrospective analysis was conducted on hospitalized 30 adults with severe dengue fever with severe hepatitis. These 30 patients had aspartate transaminase (AST) and alanine transaminases (ALT) more than 500 U/L and/or PT INR (prothrombin time and international normalized ratio) more than 1.5. They were treated with NAC infusion of 100 mg/h for 3 to 5 days. RESULTS: The mean age of the group was 49.9 ± 11.46 years and 18 (60%) patients were males. Nineteen patients (63%) developed dengue shock. Of them 12 patients (40%) developed hepatic encephalopathy. Median AST on the day of administration of NAC was 1125 U/L interquartile range (IQR) 1653.25 while median ALT was 752 (IQR 459.25). There was a statistically significant reduction of both ALT (p = 0.034) and AST (p = 0.049) from day 1 to 4 after NAC infusion. Rise of platelet count between day 1 and day 4 also showed statistically significant difference (p = 0.011) but the reduction of prothrombin time and international normalized ratio (PT/INR) from 1 to day 4 did not show statistical significance difference. Mean duration of treatment with NAC was 3.61 ± 0.75 days while mean length of hospital stay was 6.2 ± 1.27 days. Only one patient died (3.3%). None of the patients reported adverse drug reaction due to NAC. CONCLUSION: Majority of patients demonstrated marked clinical and biochemical improvements and they recovered fully. We observed faster and significant recovery of liver enzymes following administration of NAC. Based on the above findings, this study provides preliminary evidence for the beneficial effect of NAC in severe hepatitis in dengue infection with greater survival benefits.
format Online
Article
Text
id pubmed-8454086
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84540862021-09-21 Use of intravenous N-acetylcysteine in acute severe hepatitis due to severe dengue infection: a case series Dissanayake, D. M. D. I. B. Gunaratne, W. M. S. N. Kumarihamy, K. W. M. P. P. Kularatne, S. A. M. Kumarasiri, P. V. R. BMC Infect Dis Research BACKGROUND: Dengue fever is a common mosquito borne viral infection. Severe dengue fever associated severe hepatitis carries high mortality. Based on the beneficial effect of N-acetylcysteine (NAC) in paracetamol poisoning and non-acetaminophen induced liver failure, it is used in dengue fever associated hepatitis in clinical practice. We aim to study the reversal of liver enzymes with NAC in the setting of severe hepatitis due to severe dengue infection. METHODS: A retrospective analysis was conducted on hospitalized 30 adults with severe dengue fever with severe hepatitis. These 30 patients had aspartate transaminase (AST) and alanine transaminases (ALT) more than 500 U/L and/or PT INR (prothrombin time and international normalized ratio) more than 1.5. They were treated with NAC infusion of 100 mg/h for 3 to 5 days. RESULTS: The mean age of the group was 49.9 ± 11.46 years and 18 (60%) patients were males. Nineteen patients (63%) developed dengue shock. Of them 12 patients (40%) developed hepatic encephalopathy. Median AST on the day of administration of NAC was 1125 U/L interquartile range (IQR) 1653.25 while median ALT was 752 (IQR 459.25). There was a statistically significant reduction of both ALT (p = 0.034) and AST (p = 0.049) from day 1 to 4 after NAC infusion. Rise of platelet count between day 1 and day 4 also showed statistically significant difference (p = 0.011) but the reduction of prothrombin time and international normalized ratio (PT/INR) from 1 to day 4 did not show statistical significance difference. Mean duration of treatment with NAC was 3.61 ± 0.75 days while mean length of hospital stay was 6.2 ± 1.27 days. Only one patient died (3.3%). None of the patients reported adverse drug reaction due to NAC. CONCLUSION: Majority of patients demonstrated marked clinical and biochemical improvements and they recovered fully. We observed faster and significant recovery of liver enzymes following administration of NAC. Based on the above findings, this study provides preliminary evidence for the beneficial effect of NAC in severe hepatitis in dengue infection with greater survival benefits. BioMed Central 2021-09-20 /pmc/articles/PMC8454086/ /pubmed/34544380 http://dx.doi.org/10.1186/s12879-021-06681-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Dissanayake, D. M. D. I. B.
Gunaratne, W. M. S. N.
Kumarihamy, K. W. M. P. P.
Kularatne, S. A. M.
Kumarasiri, P. V. R.
Use of intravenous N-acetylcysteine in acute severe hepatitis due to severe dengue infection: a case series
title Use of intravenous N-acetylcysteine in acute severe hepatitis due to severe dengue infection: a case series
title_full Use of intravenous N-acetylcysteine in acute severe hepatitis due to severe dengue infection: a case series
title_fullStr Use of intravenous N-acetylcysteine in acute severe hepatitis due to severe dengue infection: a case series
title_full_unstemmed Use of intravenous N-acetylcysteine in acute severe hepatitis due to severe dengue infection: a case series
title_short Use of intravenous N-acetylcysteine in acute severe hepatitis due to severe dengue infection: a case series
title_sort use of intravenous n-acetylcysteine in acute severe hepatitis due to severe dengue infection: a case series
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454086/
https://www.ncbi.nlm.nih.gov/pubmed/34544380
http://dx.doi.org/10.1186/s12879-021-06681-9
work_keys_str_mv AT dissanayakedmdib useofintravenousnacetylcysteineinacuteseverehepatitisduetoseveredengueinfectionacaseseries
AT gunaratnewmsn useofintravenousnacetylcysteineinacuteseverehepatitisduetoseveredengueinfectionacaseseries
AT kumarihamykwmpp useofintravenousnacetylcysteineinacuteseverehepatitisduetoseveredengueinfectionacaseseries
AT kularatnesam useofintravenousnacetylcysteineinacuteseverehepatitisduetoseveredengueinfectionacaseseries
AT kumarasiripvr useofintravenousnacetylcysteineinacuteseverehepatitisduetoseveredengueinfectionacaseseries